Leerink Partnrs Has Bearish Outlook for Bruker Q1 Earnings

Bruker Co. (NASDAQ:BRKR) – Equities researchers at Leerink Partnrs cut their Q1 2025 earnings estimates for Bruker in a report released on Thursday, February 13th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.41 per share for the quarter, down from their previous forecast of $0.54. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Leerink Partnrs also issued estimates for Bruker’s Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.98 EPS, FY2026 earnings at $3.12 EPS and FY2027 earnings at $3.60 EPS.

Other equities analysts also recently issued reports about the stock. Bank of America upped their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, December 13th. TD Cowen decreased their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Guggenheim reissued a “buy” rating on shares of Bruker in a research note on Friday, January 17th. Barclays decreased their price target on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Finally, Wells Fargo & Company cut their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $70.50.

Bruker Stock Performance

Shares of NASDAQ:BRKR opened at $50.75 on Monday. The company has a market cap of $7.69 billion, a price-to-earnings ratio of 24.40, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. The company has a 50-day moving average price of $57.14 and a 200-day moving average price of $60.24. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker has a 12 month low of $48.07 and a 12 month high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 9.41% and a return on equity of 21.52%.

Institutional Trading of Bruker

Several institutional investors and hedge funds have recently modified their holdings of the company. True Wealth Design LLC increased its holdings in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 510 shares during the last quarter. Eagle Bay Advisors LLC increased its holdings in Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 674 shares during the last quarter. UMB Bank n.a. increased its holdings in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 248 shares during the last quarter. Values First Advisors Inc. bought a new stake in Bruker in the 3rd quarter valued at $73,000. Finally, GAMMA Investing LLC increased its holdings in Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 412 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.